Magnus Financial Group’s AIM ImmunoTech AIM Stock Holding History

Magnus Financial Group’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-140	Closed	-$35K	–	715
2020 Q2	$35K	Buy	+140	New	+$34K	﹤0.01%	676

Other funds holding AIM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SWM

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Magnus Financial Group's AIM Position: Q3 2020 in Review

Magnus Financial Group sold out of AIM ImmunoTech (AIM) in Q3 2020, closing a stake of 140 shares — an estimated $35K sold.

Magnus Financial Group first reported a position in AIM in Q2 2020 and held it in 1 quarter. The position peaked at $35K in Q2 2020. 32 funds tracked by Wall St. Rank hold AIM as of Q3 2020.

Magnus Financial Group reported no remaining AIM ImmunoTech position as of Q3 2020 after selling out during the quarter.
Magnus Financial Group sold 140 AIM ImmunoTech shares in Q3 2020, an estimated $35K.
Magnus Financial Group first reported a position in AIM ImmunoTech in Q2 2020 and held it in 1 quarter.
Magnus Financial Group's AIM ImmunoTech position peaked at $35K in Q2 2020.
32 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q3 2020.

Based on Magnus Financial Group's 13F filing for Q3 2020, filed 5 Nov 2020.